Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Semin Oncol. 2015 Jun 3;42(4):562–572. doi: 10.1053/j.seminoncol.2015.05.012

Table 1.

Examples of Monoclonal Antibodies (mAbs) with clinical antitumor efficacy, acting via innate immune mechanisms for Cancer Treatment

Name Target Indication Predominant Innate Immune Mechanism of Action
Alemtuzumab CD52 B-cell CLL, CTCL CMC
Cetuximab EGFR Head/Neck and Colorectal Cancers ADCC
Dinutuximab GD2 Neuroblastoma ADCC
Obinutuzumab CD20 CLL ADCC
Ofatumumab CD20 CLL ADCC
Panitumumab EGFR Colorectal Cancers ADCC
Pertuzumab Her2 Breast Cancer ADCC
Rituximab CD20 B-cell NHL ADCC
Trastuzumab Her2/Neu Breast Cancer ADCC

CLL, chronic lymphocytic leukemia; CTCL, cutaneous T-cell lymphoma; CMC, complement mediated cytotoxicity; EGFR, epidermal growth factor receptor; ADCC, antibody dependent cell-mediated cytotoxicity; NHL, non-Hodgkin lymphoma